NGM Biopharmaceuticals Inc. Stock News

NGM Biopharmaceuticals (NGM – Research Report) received a Buy rating and a $40.00 price target from Chardan Capital analyst Michael

Barrick Gold recently reported that its Nevada Gold Mines exceeded expectations for the first 12 months of its operations.

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm

The FDA decision has wiped out more than a third of Intercept’s market cap. Yet, the company remains the front runner in the NASH space. The current trading mul

Intercept Pharmaceuticals Inc. shares plummeted Monday as U.S. regulators dashed hopes for an accelerated approval of what investors thought would be the first medicine to treat tens of millions of pe

UBS Group AG cut its stake in shares of NGM Biopharmaceuticals (NYSE:NGM) by 60.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The

JPMorgan Chase & Co. trimmed its holdings in NGM Biopharmaceuticals (NYSE:NGM) by 14.7% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 243,442 s

NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) Adverum Biotechnologies Inc...

By Jonathan Saul LONDON, June 15 (Reuters) – Three Greece-based shipping firms said they have halted trade with Venezuela after the United States imposed sanctions on vessels under their mana…

Three Greece-based shipping firms said they have halted trade with Venezuela after the United States imposed sanctions on vessels under their management, as Washington ramps up commercial heat on Cara

Greek ship managers halt Venezuela trade as U.S. sanctions bite

Russell Investments Group Ltd. acquired a new stake in NGM Biopharmaceuticals (NYSE:NGM) in the 1st quarter, Holdings Channel reports. The firm acquired 32,122 shares of the company’s stock, valued

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today